Skip to main contentSkip to navigation
Sirius Investors

SPHRY Stock: Starpharma Holdings Limited Stock Price, Analysis & Insights

Get live SPHRY stock price $5.10, comprehensive Starpharma Holdings Limited stock analysis, charts, news, and expert forecast. Real-time SPHRY stock data and investment insights.

5.10
0.00%Today
SPHRYStarpharma Holdings Limited • Other OTC • Healthcare
Market Cap
214.67M
Volume
500
52W High
5.70
52W Low
0.55

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a...

Company Information

CEO
Cheryl Maley
Sector
Healthcare
Industry
Biotechnology
Employees
40

Contact Information

Address
4-6 Southampton Crescent
Country
AU

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.77) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Starpharma Holdings Limited shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Starpharma Holdings Limited
  • Investors should consider how Starpharma Holdings Limited fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

214.67M

P/E Ratio (TTM)

-85.00

Beta

0.77

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.